Fortune writer John Simons opines that a rumored [1]Â merger of Pfizer and Wyeth would be all wrong for both companies. In his view, a merger would amount to a marriage [2]Â of weaknesses [3]. Pfizer needs blockbusters to overcome looming patent expirations and Wyeth has recently been failing to deliver.
"Would the idea behind the merger be that misery loves company?" says Standard & Poors pharma analyst Herman Saftlas. "Most mergers in this sector haven't panned out from an earnings growth perspective. But even worse, these two companies are in the same boat."
- read Simon's opinion piece [4]
Related Articles:
Wyeth buyout a good deal for Pfizer? Report [1]
What's next for Pfizer? Report [5]
Wyeth stumbles badly trying to develop new drugs. Report [6]
Links:
[1] http://www.fiercepharma.com/story/wyeth-buyout-good-deal-pfizer/2007-08-21
[2] http://www.fiercebiotech.com/story/troubled-pfizer-blueprints-biotech-venture-effort/2007-08-02
[3] http://www.fiercepharma.com/story/wyeth-stock-down-after-several-setbacks/2007-08-13
[4] http://money.cnn.com/2007/08/24/magazines/fortune/simons_pharma.fortune/index.htm?postversion=2007082409
[5] http://www.fiercebiotech.com/story/what-s-next-for-pfizer/2006-12-05
[6] http://www.fiercebiotech.com/story/wyeth-stumbles-badly-trying-develop-new-drugs/2007-08-13